CENTOGENE Man and Woman on the Couch

Somatic Mutation Testing

Testing for the presence of cancer requires the utmost personal care and consideration. Somatic mutation testing is enormously beneficial for improving the prognosis and the quality of life of cancer-affected patients. Our team of hereditary and somatic cancer experts will support you during every step of the process.

Our portfolio for somatic mutation testing

Identifying Somatic Mutations for Tumor Profiling

Every cancer cell can evolve its own pattern of mutated genes.

Each person's cancer, and even parts of a single tumor, can become completely unique. This has implications with respect to diagnosis, prognosis and treatment response. The presence of recurrent somatic mutations allows us to create a detailed molecular fingerprint of the tumor and to identify important tumor subtypes.


Distinctive product offering centered around high-quality genetic testing

Strong presence in and access to countries with a high prevalence of rare diseases

CentoCard provides easy logistics for central testing

Rare disease-centric Bio/Databank generates best-in-class medical insights

Deep expertise in rare, metabolic, and neurodegenerative diseases, as well as multiomics enables better diagnostics

CENTOGENE Holding the Hand of an Elderly Lady

Somatic Mutation Testing for Myeloid Tumors

Genetic testing of myeloid tumors can help you make accurate diagnoses, provide prognoses, choose appropriate therapy and counsel patients

Learn more

Doctor and woman look down

Single-Gene-Specific Somatic Mutation Testing

CENTOGENE's somatic mutation tests are highly sensitive, easy to use, and accuratly identify even low frequency variants successfully.

Learn more

How Can Somatic Genetic Testing Help Patient Care?

Somatic mutation analysis is a standard of practice for tumors in order to identify therapeutic sensitizing and resistance mutations. This allows a finer assessment of the diagnosis and prognosis and targeted therapies directed towards the individual patients tumor profile.

What Do We Know About Somatic Mutations?

Cancer is one of the leading causes of morbidity and mortality worldwide. Cancer can be the result of a genetic predisposition that is inherited from family members (germline (hereditary) gene mutation) or it can be the result of the acquired mutations accumulated during a lifetime (somatic (acquired) mutation).

Unlike regular cells, cancer cells do not experience physiological elimination of “programmed cell death” or “apoptosis”; instead they continue to grow and divide. Tumor cells show uncontrolled proliferation if there are mutations in the genes involved in cell division .


Hotspot targeted mutation testing is unavailable in the US for the following mutations: BRAF c.1799T>A p.V600E, EGFR c.2573T>G, p.L858R, KRAS c.35G>A, p.G12D, KRAS c.38G>A, p.G13D, KRAS c.35G>T p.G12V, NRAS c.181C>A p.Q61K, NRAS c.34G>T, p.G12C, NRAS c.35G>A, p.G12D, NRAS c.182A>G, p.Q61R.



Product Sheets

CENTOGENE Solid Tumor Panel Productsheet English PDF

Solid Tumor Panel – Product Sheet

Providing knowledge to battle cancer

CENTOGENE Myeloid Productsheet English PDF

Myeloid Tumor Panel – Product Sheet

The targeted approach to detecting myeloid malignancies

Sample Reports

CENTOGENE Solid Tumor Panel Positive Sample Report PDF

Solid Tumor Panel – Sample Report, Positive


Scientific Publications

Understanding DNA Alterations in Colorectal Cancer

Germline and somatic DNA alterations may cause inherited diseases and/or cancer. While CENTOGENE’s routine diagnostic focus is on the former, we frequently address oncological questions in research […]

Dec 18, 2019
  • Oncology
  • WES

Related Webinars

Oncogenetics in the Clinical Practice

In this webinar you will learn the last insights in oncogenetics testing and how CENTOGENE gene panels can support you to assess the risk of a patient to develop an inherited cancer.

Oct 26, 2016
  • Oncology
  • WGS
  • BRCA 1/2
  • Hereditary Cancer

Get in Touch With Our Customer Support

Our consultation service is available in several languages.

+49 (0) 381 80 113 - 416

Mon. – Fri. 7 a.m. – 8 p.m. CEST

Sat. 8 a.m. – 12 p.m. CEST

Contact Us

For our US Partners:

+1 (617) 580 - 2102

Mon. – Fri. 9 a.m. – 5:30 p.m. EST

Contact Us